EUVIMEDEUVIMED entdecken
Crossref

Evaluation of the Therapeutic Effects of Beta2-Microglobulin Adsorption on Dialysis-Related Amyloidosis Using a Clinical Claims Database

Chikao Onogi, Akihito Tanaka, Kazuhiro Furuhashi, Shoichi Maruyama

Blood Purification · 2025

DOI: 10.1159/000547964 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood Purification, 2025. Verfasst von Chikao Onogi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Nagoya University, Graduate School of Medicine, Nagoya, Japan. Hauptthemen laut MEDLINE: beta 2-Microglobulin, Amyloidosis, Renal Dialysis, Hemodiafiltration. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Dialysis-related amyloidosis (DRA) is a refractory complication of long-term dialysis caused by β2-microglobulin (β2MG) deposition. While β2MG adsorption columns remove β2MG, their impact on preventing re-surgery remains unclear.

Methods

This a noninterventional, population-based cohort study used a large-scale medical claims database. This study included patients with chronic kidney disease undergoing maintenance hemodialysis (HD) and diagnosed with DRA. The exposure group received β2MG adsorption column therapy, while the control group was divided into online hemodiafiltration (OHDF) and HD subgroups. The primary endpoint was carpal tunnel or trigger finger release.

Results

Among 3,946 eligible patients, 212 patients in the β2MG adsorption column group, 139 in the OHDF group, and 237 in the HD group were included; the primary endpoint occurred in 28 (13.2%), 21 (15.1%), and 37 (15.6%) patients, respectively. Although there was a trend toward a lower incidence in the β2MG adsorption column group, no significant difference was observed (p = 0.43). The adjusted hazard ratio for the β2MG adsorption column group (HD group as reference) tended to be low (0.68, 95% CI: 0.41–1.13), but this difference was not significant.

Conclusions

Although there was no statistically significant difference, the findings suggest that the β2MG adsorption column may help slow DRA progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta 2-MicroglobulinAmyloidosisRenal DialysisHemodiafiltrationRenal Insufficiency, ChronicHumansMaleFemaleMiddle AgedAgedAdsorptionDatabases, Factual

Stichwörter der Autor:innen

AmyloidosisClinical claims databaseDialysisDialysis-related amyloidosisβ2-Microglobulin

Substanzen

beta 2-Microglobulin

Autor:innen und Institutionen

  • Department of Nephrology, Nagoya University, Graduate School of Medicine, Nagoya, Japan.
  • Department of Cell Physiology, Nagoya University, Graduate School of Medicine, Nagoya, Japan.
  • Department of Nephrology, Nagoya University Hospital, Nagoya, Japan.
  • Department of Nephrology, Nagoya University Hospital, Nagoya, Japan, furu13@med.nagoya-u.ac.jp.

Zitieren

APA

Onogi, C., Tanaka, A., Furuhashi, K., & Maruyama, S. (2025). Evaluation of the Therapeutic Effects of Beta2-Microglobulin Adsorption on Dialysis-Related Amyloidosis Using a Clinical Claims Database. Blood Purification. https://doi.org/10.1159/000547964

Vancouver

Onogi C, Tanaka A, Furuhashi K, Maruyama S. Evaluation of the Therapeutic Effects of Beta2-Microglobulin Adsorption on Dialysis-Related Amyloidosis Using a Clinical Claims Database. Blood Purification. 2025. doi:10.1159/000547964

BibTeX
@article{Onogi2025,
  author = {Onogi, Chikao and Tanaka, Akihito and Furuhashi, Kazuhiro and Maruyama, Shoichi},
  title = {Evaluation of the Therapeutic Effects of Beta2-Microglobulin Adsorption on Dialysis-Related Amyloidosis Using a Clinical Claims Database},
  journal = {Blood Purification},
  year = {2025},
  doi = {10.1159/000547964}
}
Kostenlos starten →